Antibody-mediated rejection (AMR) is a major complication after ABO-incompatible liver transplantation. According to the 2016 Banff Working Group on Liver Allograft Criteria for the diagnosis of acute AMR, a positive serum donor specific antibody (DSA) is needed. On the other hand, the clinical significance of the histological findings of AMR in the absence of DSA is unclear. This paper describes a 57-year-old man (blood type, O+) who suffered from hepatitis B virus cirrhosis with hepatocellular carcinoma.
INTRODUCTION
After the first liver allo-transplantation was performed in the 1960s, the liver was considered an "immune tolerogenic organ" (1) . However, in 1989, Gugenheim et al. (2) reported allograft rejection in ABO-incompatible liver transplantation (ABOi-LT). In a total of 17 ABOi-LT recipients, six showed graft failure due to impaired immune responses and antibody-mediated rejection (AMR). To avoid AMR, various desensitization methods have been developed. The protocol for ABOi-LT consists of pre-operative intravenous ritux-imab (RTX), multiple session of plasmapheresis (PP), local infusion therapy, or splenectomy. After administration of RTX, an anti-cluster of differentiation 20 (CD20) monoclonal antibody, in ABOi-LT, Usuda et al. (3) showed that the incidence of AMR in ABOi-LT was markedly reduced; indeed, recent outcomes were found to be comparable to those of ABO-compatible-LT (3, 4) . However, AMR is still a major complication after ABOi-LT. According to the 2016 Banff Working Group on Liver Allograft Criteria for the diagnosis of acute AMR requires the positive serum donor specific antibody (DSA) (5) . However, clinical significance of histological findings of AMR in the absence of DSA is unclear. Here, we present the case of allograft injury like AMR under the absence of DSA after ABOi-LT with the low titers of anti-ABO antibody and depleted serum CD19+ B cells. A recent study reported that high pre-operative antibody titers did not have a significant effect on AMR. Instead, it is important to prevent new antibody production after transplantation (7) . However, in general, desensitization protocols have been directed toward the elimination of anti-ABO an- Recent studies have evaluated the effects of DSA on short-and long-term prognosis. In the past, preformed DSA was generally considered to be clinically unrelated to liver allograft outcomes (8) (9) (10) (11) . However, recent studies have confirmed inferior clinical outcomes in some but not all DSA-positive patients (12) . For this reason, many transplantation centers have performed cross-matching tests with DSA before transplantation to reduce the possibility of rejection. In our patient, the status of DSA before and after transplantation was negative. Although, clinical significance of DSA (−) AMR is unclear, it has been shown that the treatment improves histopathologic changes in this case. In ABOi-LT, investigations for immediate histologic allograft injury similar to AMR might be needed to know its clinical significance.
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